Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development

Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. Compared to the effect of placebo, it improved both progression-f...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Hematol Oncol
Autori principali: Shen, Guoshuang, Zheng, Fangchao, Ren, Dengfeng, Du, Feng, Dong, Qiuxia, Wang, Ziyi, Zhao, Fuxing, Ahmad, Raees, Zhao, Jiuda
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2018
Soggetti:
Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6146601/
https://ncbi.nlm.nih.gov/pubmed/30231931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-018-0664-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi